328 related articles for article (PubMed ID: 26992248)
1. Ritonavir-boosted danoprevir plus peginterferon alfa-2a and ribavirin in Asian chronic hepatitis C patients with or without cirrhosis.
Kao JH; Tung SY; Lee Y; Thongsawat S; Tanwandee T; Sheen IS; Wu JJ; Li H; Brennan BJ; Zhou J; Le Pogam S; Najera I; Thommes JA; Hill G
J Gastroenterol Hepatol; 2016 Oct; 31(10):1757-1765. PubMed ID: 26992248
[TBL] [Abstract][Full Text] [Related]
2. Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients.
Gane EJ; Rouzier R; Stedman C; Wiercinska-Drapalo A; Horban A; Chang L; Zhang Y; Sampeur P; Nájera I; Smith P; Shulman NS; Tran JQ
J Hepatol; 2011 Nov; 55(5):972-9. PubMed ID: 21354234
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of danoprevir-ritonavir plus peginterferon alfa-2a-ribavirin in hepatitis C virus genotype 1 prior null responders.
Gane EJ; Rouzier R; Wiercinska-Drapalo A; Larrey DG; Morcos PN; Brennan BJ; Le Pogam S; Nájera I; Petric R; Tran JQ; Kulkarni R; Zhang Y; Smith P; Yetzer ES; Shulman NS
Antimicrob Agents Chemother; 2014; 58(2):1136-45. PubMed ID: 24295986
[TBL] [Abstract][Full Text] [Related]
4. DAUPHINE: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha-2a/ribavirin in HCV genotypes 1 or 4.
Everson G; Cooper C; Hézode C; Shiffman ML; Yoshida E; Beltran-Jaramillo T; Andreone P; Bruno S; Ferenci P; Zeuzem S; Brunda M; Le Pogam S; Nájera I; Zhou J; Navarro MT; Voulgari A; Shulman NS; Yetzer ES
Liver Int; 2015 Jan; 35(1):108-19. PubMed ID: 24517252
[TBL] [Abstract][Full Text] [Related]
5. Ritonavir-boosted danoprevir-based regimens in treatment-naive and prior null responders with HCV genotype 1 or 4 and compensated cirrhosis.
Gane EJ; Rouzier R; Hassanein T; Stedman CA; Mazur W; Kupcova V; Le Pogam S; Eng S; Voulgari A; Morcos PN; Brennan BJ; Scalori A; Thommes J
Hepatol Int; 2016 May; 10(3):478-87. PubMed ID: 26886127
[TBL] [Abstract][Full Text] [Related]
6. Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection.
Marcellin P; Cooper C; Balart L; Larrey D; Box T; Yoshida E; Lawitz E; Buggisch P; Ferenci P; Weltman M; Labriola-Tompkins E; Le Pogam S; Nájera I; Thomas D; Hooper G; Shulman NS; Zhang Y; Navarro MT; Lim CY; Brunda M; Terrault NA; Yetzer ES
Gastroenterology; 2013 Oct; 145(4):790-800.e3. PubMed ID: 23811112
[TBL] [Abstract][Full Text] [Related]
7. Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin.
Feld JJ; Jacobson IM; Jensen DM; Foster GR; Pol S; Tam E; Jablkowski M; Berak H; Vierling JM; Yoshida EM; Perez-Gomez HR; Scalori A; Hooper GJ; Tavel JA; Navarro MT; Shahdad S; Kulkarni R; Le Pogam S; Nájera I; Eng S; Lim CY; Shulman NS; Yetzer ES
J Hepatol; 2015 Feb; 62(2):294-302. PubMed ID: 25239078
[TBL] [Abstract][Full Text] [Related]
8. Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR study.
Gane EJ; Pockros PJ; Zeuzem S; Marcellin P; Shikhman A; Bernaards C; Zhou J; Yetzer ES; Ballester R; Dwyer C; Tong X; Nájera I; Bertasso A; Hammond J; Kindrick A; Morcos PN; Smith P; Stancic S; Shulman NS
Liver Int; 2015 Jan; 35(1):79-89. PubMed ID: 24814388
[TBL] [Abstract][Full Text] [Related]
9. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
[TBL] [Abstract][Full Text] [Related]
10. Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial.
Reddy KR; Zeuzem S; Zoulim F; Weiland O; Horban A; Stanciu C; Villamil FG; Andreone P; George J; Dammers E; Fu M; Kurland D; Lenz O; Ouwerkerk-Mahadevan S; Verbinnen T; Scott J; Jessner W
Lancet Infect Dis; 2015 Jan; 15(1):27-35. PubMed ID: 25482330
[TBL] [Abstract][Full Text] [Related]
11. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
Torriani FJ; Rodriguez-Torres M; Rockstroh JK; Lissen E; Gonzalez-García J; Lazzarin A; Carosi G; Sasadeusz J; Katlama C; Montaner J; Sette H; Passe S; De Pamphilis J; Duff F; Schrenk UM; Dieterich DT;
N Engl J Med; 2004 Jul; 351(5):438-50. PubMed ID: 15282351
[TBL] [Abstract][Full Text] [Related]
12. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.
Chung RT; Andersen J; Volberding P; Robbins GK; Liu T; Sherman KE; Peters MG; Koziel MJ; Bhan AK; Alston B; Colquhoun D; Nevin T; Harb G; van der Horst C;
N Engl J Med; 2004 Jul; 351(5):451-9. PubMed ID: 15282352
[TBL] [Abstract][Full Text] [Related]
13. Sofosbuvir for previously untreated chronic hepatitis C infection.
Lawitz E; Mangia A; Wyles D; Rodriguez-Torres M; Hassanein T; Gordon SC; Schultz M; Davis MN; Kayali Z; Reddy KR; Jacobson IM; Kowdley KV; Nyberg L; Subramanian GM; Hyland RH; Arterburn S; Jiang D; McNally J; Brainard D; Symonds WT; McHutchison JG; Sheikh AM; Younossi Z; Gane EJ
N Engl J Med; 2013 May; 368(20):1878-87. PubMed ID: 23607594
[TBL] [Abstract][Full Text] [Related]
14. Interferon-free regimens containing setrobuvir for patients with genotype 1 chronic hepatitis C: a randomized, multicenter study.
Jensen DM; Brunda M; Elston R; Gane EJ; George J; Glavini K; Hammond JM; Le Pogam S; Nájera I; Passe S; Piekarska A; Rodriguez I; Zeuzem S; Chu T;
Liver Int; 2016 Apr; 36(4):505-14. PubMed ID: 26519669
[TBL] [Abstract][Full Text] [Related]
15. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M
Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225
[TBL] [Abstract][Full Text] [Related]
16. Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1.
Jacobson I; Zeuzem S; Flisiak R; Knysz B; Lueth S; Zarebska-Michaluk D; Janczewska E; Ferenci P; Diago M; Zignego AL; Safadi R; Baruch Y; Abdurakhmanov D; Shafran S; Thabut D; Bruck R; Gadano A; Thompson AJ; Kopit J; McPhee F; Michener T; Hughes EA; Yin PD; Noviello S
World J Gastroenterol; 2016 Mar; 22(12):3418-31. PubMed ID: 27022224
[TBL] [Abstract][Full Text] [Related]
17. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
Hézode C; Forestier N; Dusheiko G; Ferenci P; Pol S; Goeser T; Bronowicki JP; Bourlière M; Gharakhanian S; Bengtsson L; McNair L; George S; Kieffer T; Kwong A; Kauffman RS; Alam J; Pawlotsky JM; Zeuzem S;
N Engl J Med; 2009 Apr; 360(18):1839-50. PubMed ID: 19403903
[TBL] [Abstract][Full Text] [Related]
18. Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort.
Foster GR; Coppola C; Derbala M; Ferenci P; Orlandini A; Reddy KR; Tallarico L; Shiffman ML; Ahlers S; Bakalos G; Hassanein T;
PLoS One; 2016; 11(3):e0151703. PubMed ID: 27018988
[TBL] [Abstract][Full Text] [Related]
19. Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C.
Buti M; Agarwal K; Horsmans Y; Sievert W; Janczewska E; Zeuzem S; Nyberg L; Brown RS; Hézode C; Rizzetto M; Paraná R; De Meyer S; De Masi R; Luo D; Bertelsen K; Witek J
Gastroenterology; 2014 Mar; 146(3):744-753.e3. PubMed ID: 24316262
[TBL] [Abstract][Full Text] [Related]
20. Peginterferon alfa-2a and peginterferon alfa-2b combined with ribavirin in patients with genotype 1 chronic hepatitis C: results of a prospective single-centre study.
Berak H; Laskus T; Kołakowska-Rządzka A; Wasilewski M; Stańczak JJ; Bardadin K; Walewska-Zielecka B; Horban A
Adv Med Sci; 2014 Sep; 59(2):261-5. PubMed ID: 25117425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
